|
|
News Breaks | | | | October 23, 2012 | | 07:34 EDT |  | AMRN | Amarin announces issuance of two U.S. patents for Vascepa
Amarin announced that the U.S. Patent and Trademark Office, or USPTO, has issued two patents covering the use of Amarin's VascepaTM capsules based on U.S. Patent Application Serial Nos. 12/702,889 and 13/349,153, both titled "Methods of Treating Hypertriglyceridemia." On Sept. 5, Amarin announced the issuance of Notices of Allowance for claims under these applications. The newly issued patents, U.S. Patent Numbers 8,793,727 and 8,293,728, have patent terms that each expire no earlier than in 2030. Amarin plans to list both patents in the U.S. FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or Orange Book. Amarin now has eight U.S. patents either issued or allowed as well as over 30 additional patent applications currently in prosecution in the U.S.. Amarin is also pursuing patent applications related to Vascepa in multiple jurisdictions outside the U.S., including the application for Amarin's MARINE method of use patent in Europe for which Amarin has announced receipt of an Intention to Grant letter. | |
|
News For AMRN From The Last 14 Days Check below for free stories on AMRN the last two weeks. |
|
|
| May 23, 2013 | | 11:55 EDT |  | AMRN | Options with decreasing implied volatility: AEGR PXP AMRN DSX ACT
 Subscribe for More Information | | | May 22, 2013 | | 11:56 EDT | | AMRN | Options with decreasing implied volatility: WCRX NTI PXP AMRN BBY
| | | 06:07 EDT | | AMRN | Amarin announces patent allowance related to combination of Vascepa, Statin
Amarin announced that the United States Patent and Trademark Office has published notification of a Notice of Allowance for Amarin's U.S. Patent Application Serial Number 13/417,899 titled "Pharmaceutical Compositions Comprising EPA and a Cardiovascular Agent and Methods of Using the Same." This application includes claims intended to protect the Vascepa indication approved by the FDA based on Amarin's MARINE clinical trial results specifically those results seen in patients on statin therapy. The claims in this allowed application cover a method to reduce triglycerides in subjects having a triglyceride level of 500mg/dl to 1500mg/dl who are also receiving statin therapy using an amount of Vascepa effective to reduce triglycerides without substantially increasing low density lipoprotein cholesterol. | | | May 21, 2013 | | 11:41 EDT | | AMRN | Options with decreasing implied volatility: SGMO WCRX NTI TSLA AMRN
| | | May 17, 2013 | | 14:12 EDT | | AMRN | Amarin shares slip after FDA updates Orange Book
Subscribe for More Information | | | May 15, 2013 | | 11:04 EDT |  | AMRN | Amarin management to meet with Lazard Capital
Meeting to be held in the Mid-Atlantic area on May 16 hosted by Lazard Capital. | | | May 13, 2013 | | 12:52 EDT | | AMRN | Amarin strength attributed to MassHealth drug list addition
Subscribe for More Information | | | May 10, 2013 | | 09:23 EDT |  | AMRN | Amarin continues to make progress with payors, says Leerink
Leerink reiterates an Outperform rating on shares of Amarin following the company's Q1 results. The firm believes Amarin continues to make good progress with payors and that Vascepa script trends are tracking well. | |
|
|
|
|
|
|
